Prostate MRI and Molecular Imaging: Core and Advanced Applications (2022)-M1-CGU02-2022

Video Transcription

Video Summary

The discussion focuses on the role and advancements of PSMA-PET and PET-MR in initial staging of prostate cancer. PSMA-PET is particularly effective for detecting metastatic disease, outperforming traditional imaging modalities like bone scans and CT. Advances in PET scanner technology and radiopharmaceuticals, such as those providing a higher signal-to-noise ratio, have improved the detection of small prostate cancer sites. Studies have demonstrated that PSMA-PET offers superior specificity and sensitivity, particularly for larger nodal metastases, enhancing staging accuracy. Also discussed is the potential complimentary role of PSMA-PET with MRI, particularly in cases of PSMA-negative or low-expression disease. Furthermore, improvements in MRI reading and biopsy strategies are suggested to reduce false positives and enhance diagnostic accuracy. The introduction of AI in prostate imaging is also highlighted, serving as a tool to improve detection and reduce interpretative variability, thus potentially overcoming issues of inconsistent MRI performance. Lastly, the risk-based MRI pathway is proposed to balance benefits and harms in cancer detection, particularly by using PSA density adjustments to decide biopsy necessity.

Keywords

PSMA-PET

PET-MR

prostate cancer staging

metastatic disease detection

radiopharmaceutical advancements

AI in prostate imaging

MRI diagnostic accuracy